LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Home・Akciju saraksts・Simulations Plus Inc

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

11.59 -0.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.49

Max

11.67

Galvenie mērījumi
By Trading Economics
Ienākumi	1.4M 676K
Pārdošana	961K 18M
Dividenžu ienesīgums	0.48
Peļņas marža	3.67
Darbinieki	212
EBITDA	-3M 2.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+62.81% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.48% 2.47%
Nākamie ieņēmumi	2026. g. 2. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-124M 244M
Iepriekšējā atvēršanas cena	12.36
Iepriekšējā slēgšanas cena	11.59

Ziņu noskaņojums

By Acuity

50%

165 / 350 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. marts 17:19 UTC

Galvenie ziņu notikumi

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

2026. g. 20. marts 16:56 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

2026. g. 20. marts 16:56 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

2026. g. 20. marts 16:45 UTC

Galvenie ziņu notikumi

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

2026. g. 20. marts 16:22 UTC

Galvenie ziņu notikumi

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

2026. g. 20. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 20. marts 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 20. marts 19:55 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude Closes Out Volatile Week Higher -- Market Talk

2026. g. 20. marts 19:28 UTC

Tirgus saruna

Galvenie ziņu notikumi

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

2026. g. 20. marts 19:28 UTC

Iegādes, apvienošanās, pārņemšana

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

2026. g. 20. marts 18:39 UTC

Tirgus saruna

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

2026. g. 20. marts 18:31 UTC

Iegādes, apvienošanās, pārņemšana

Honeywell Announces Pricing of Debt Tender Offers >HON

2026. g. 20. marts 18:19 UTC

Iegādes, apvienošanās, pārņemšana

Why Mayo and Soap No Longer Mix for Unilever -- Update

2026. g. 20. marts 18:15 UTC

Tirgus saruna

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

2026. g. 20. marts 17:57 UTC

Tirgus saruna

U.S. Oil Rig Count Inches Up -- Market Talk

2026. g. 20. marts 17:04 UTC

Galvenie ziņu notikumi

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

2026. g. 20. marts 16:20 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 20. marts 16:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 20. marts 15:40 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

2026. g. 20. marts 15:30 UTC

Peļņas

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

2026. g. 20. marts 15:26 UTC

Tirgus saruna

Peļņas

Galvenie ziņu notikumi

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

2026. g. 20. marts 15:26 UTC

Iegādes, apvienošanās, pārņemšana

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

2026. g. 20. marts 15:25 UTC

Tirgus saruna

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

2026. g. 20. marts 15:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

2026. g. 20. marts 14:58 UTC

Galvenie ziņu notikumi

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

2026. g. 20. marts 14:55 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Lower as Speculative Pullback Extends -- Market Talk

2026. g. 20. marts 14:54 UTC

Iegādes, apvienošanās, pārņemšana

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

2026. g. 20. marts 14:53 UTC

Iegādes, apvienošanās, pārņemšana

Unilever, McCormick Deal Would Create a New Condiment King -- WSJ

2026. g. 20. marts 14:46 UTC

Tirgus saruna

U.K. Government Bonds Selloff More Pronounced Than Peers -- Market Talk

2026. g. 20. marts 14:45 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Price Forecasts For 2026-27 Raised at UBS -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

62.81% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD 62.81%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

165 / 350 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.